A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD
Status:
Not yet recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2a study to assess the the safety and tolerability of TPN-101 in patients
with Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) Associated with
Hexanucleotide Repeat Expansion in the C9orf72 gene (C9ORF72 ALS/FTD).